688 results on '"Novak, Michal"'
Search Results
52. Protein Truncation as a Common Denominator of Human Neurodegenerative Foldopathies
53. Inge Grundke-Iqbal, Ph.D. (1937–2012): the Discoverer of the Abnormal Hyperphosphorylation of Tau in Alzheimer’s Disease
54. Tau Protein Phosphorylation in Diverse Brain Areas of Normal and CRH Deficient Mice: Up-Regulation by Stress
55. High-yield purification of fetal tau preserving its structure and phosphorylation pattern
56. CSF phospho-tau correlates with behavioural decline and brain insoluble phospho-tau levels in a rat model of tauopathy
57. Cortical and Hippocampal Neurons from Truncated Tau Transgenic Rat Express Multiple Markers of Neurodegeneration
58. Chaperone-Like Antibodies in Neurodegenerative Tauopathies: Implication for Immunotherapy
59. New Age of Neuroproteomics in Alzheimer’s Disease Research
60. Misfolded tau protein and disease modifying pathways in transgenic rodent models of human tauopathies
61. Second-Generation Antibodies Neutralize Emerging SARS-CoV-2 Variants of Concern
62. Intrinsically Disordered Proteins in the Neurodegenerative Processes: Formation of Tau Protein Paired Helical Filaments and Their Analysis: Intrinsically Disordered Tau Protein in Neurodegeneration
63. Neuro-immune proteomic crosstalk in health and disease: partners in love, partners in divorce
64. Neurodegeneration caused by expression of human truncated tau leads to progressive neurobehavioural impairment in transgenic rats
65. Mesenchymal Stromal Cells and Neural Stem Cells Potential for Neural Repair in Spinal Cord Injury and Human Neurodegenerative Disorders
66. Alzheimer’s-disease-associated conformation of intrinsically disordered tau protein studied by intrinsically disordered protein liquid-phase competitive enzyme-linked immunosorbent assay
67. Environmental Enrichment Rescues Functional Deficit and Alters Neuroinflammation in a Transgenic Model of Tauopathy
68. Rat tau proteome consists of six tau isoforms: implication for animal models of human tauopathies
69. Protein kinase C and calcium/calmodulin-dependent protein kinase II phosphorylate three-repeat and four-repeat tau isoforms at different rates
70. Truncated tau expression levels determine life span of a rat model of tauopathy without causing neuronal loss or correlating with terminal neurofibrillary tangle load
71. Expression of a truncated tau protein induces oxidative stress in a rodent model of tauopathy
72. Promotion of Hyperphosphorylation by Frontotemporal Dementia Tau Mutations
73. Rapid purification of truncated tau proteins: model approach to purification of functionally active fragments of disordered proteins, implication for neurodegenerative diseases
74. A rapid immunohistochemical primary screening assay for hybridomas
75. The Neuronal Microtubule-Associated Protein Tau Is a Substrate for Caspase-3 and an Effector of Apoptosis
76. Who fans the flames of Alzheimer's disease brains? Misfolded tau on the crossroad of neurodegenerative and inflammatory pathways
77. Genetic background modifies neurodegeneration and neuroinflammation driven by misfolded human tau protein in rat model of tauopathy: implication for immunomodulatory approach to Alzheimer's disease
78. Erratum to: Inge Grundke-Iqbal, Ph.D. (1937–2012): the Discoverer of the Abnormal Hyperphosphorylation of Tau in Alzheimer’s Disease
79. Novel mutations in TLR genes cause hyporesponsiveness to Mycobacterium avium subsp. paratuberculosis infection
80. Interaction of Tau Isoforms with Alzheimer's Disease Abnormally Hyperphosphorylated Tau and in VitroPhosphorylation into the Disease-like Protein
81. Additional file 1: of FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimerâ s disease
82. A Progressive Deposition of Paired Helical Filaments (PHF) in the Brain Characterizes the Evolution of Dementia in Alzheimerʼs Disease.: An Immunocytochemical Study with a Monoclonal Antibody Against the PHF Core
83. Strategic Advertising Management: The Case of the Transportation and Storage Market in the Czech Republic
84. Ten Years of Tau-Targeted Immunotherapy: The Path Walked and the Roads Ahead
85. Dendritic Cells as an Alternate Approach for Treatment of Neurodegenerative Disorders
86. Tau Conformation as a Target for Disease-Modifying Therapy: The Role of Truncation
87. Novel mutations in the toll like receptor genes cause hyporesponsiveness to Mycobacterium avium subsp. paratuberculosis infection
88. Anisotropic nanoscratch resistance of WC grains in WC–Co composite
89. Composition in EL-hyperstructures
90. Abstracts from the 20th International Symposium on Signal Transduction at the Blood-Brain Barriers
91. The Distance between N and C Termini of Tau and of FTDP-17 Mutants Is Modulated by Microtubule Interactions in Living Cells
92. Neuronal Expression of Truncated Tau Efficiently Promotes Neurodegeneration in Animal Models: Pitfalls of Toxic Oligomer Analysis
93. Determination of Evans blue as a blood–brain barrier integrity tracer in plasma and brain tissue by UHPLC/UV method
94. Changes of Cerebrospinal Fluid Peptides due to Tauopathy
95. An evaluation of components offset and solder spreadability using factorial experiments
96. Hyperphosphorylation induces self-assembly of [Tau] into tangles of paired helical filaments/straight filaments
97. Human Truncated Tau Induces Mature Neurofibrillary Pathology in a Mouse Model of Human Tauopathy
98. Exaggerated phosphorylation of brain tau protein in CRH KO mice exposed to repeated immobilization stress
99. O4‐08‐01: Characterisation of the Antibody Response to AADVAC1: The First‐in‐Kind Active Vaccine Against Neurofibrillary TAU Pathology
100. O4-04-06: The First Tau Vaccine for Therapy of Alzheimer's Disease and FTLD: From Tau Structure to Human Clinical Trials
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.